Synergy Pharmaceuticals Appoints Marino Garcia as Senior Vice President, Corporate Development

  Synergy Pharmaceuticals Appoints Marino Garcia as Senior Vice President,
  Corporate Development

Business Wire

NEW YORK -- March 13, 2014

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today the appointment of
Marino Garcia as Senior Vice President, Corporate Development. In this newly
created position reporting directly to the CEO, Mr. Garcia will play a
critical leadership role in Synergy’s strategic corporate planning and
business development activities.

Marino Garcia, Senior Vice President of Corporate Development for Synergy
Pharmaceuticals Inc. (Phot ...

Marino Garcia, Senior Vice President of Corporate Development for Synergy
Pharmaceuticals Inc. (Photo: Business Wire)

“Marino brings a tremendous level of experience to Synergy in areas that will
greatly benefit from his insights and leadership skills,” said Dr. Gary S.
Jacob, Chief Executive Officer of Synergy. “We look forward to his
contributions as we continue to move plecanatide closer to market and explore
new opportunities that further drive shareholder value.”

“I am excited to be joining Synergy,” said Marino Garcia, Senior Vice
President of Corporate Development for Synergy. “This company has quickly
transitioned from a small biotech start-up to a late-stage drug development
company with major clinical milestones in the near term. Synergy is well
positioned to be a key player in a very dynamic gastrointestinal market.”

Immediately prior to joining Synergy, Mr. Garcia served as Vice President of
Global Business Development at Aptalis Pharma, a privately held specialty
company focused on the gastrointestinal and cystic fibrosis markets. From 2006
to 2010, Mr. Garcia served as Vice President of US Commercial Operations and
New Product Development at Aspreva Pharmaceuticals, which was acquired by
Zurich-based Vifor Pharmaceuticals in 2008. Earlier in his career, Mr. Garcia
served in various U.S. and International leadership roles of increasing
responsibility at Eli Lilly & Co, Schering Plough, and Pfizer. Mr. Garcia
received a Bachelor’s Degree in Business Administration from Concordia
University in Montreal, Quebec, and an M.B.A. from the Richard Ivey School of
Business at Western University in London, Ontario.

About Synergy

Synergy Pharmaceuticals Inc. is a biotechnology company focused on the
research and development of novel drugs for the treatment of gastrointestinal
(GI) diseases and disorders. Synergy has discovered proprietary analogs of the
human GI hormone, uroguanylin, the natural agonist for the intestinal
guanylate cyclase-C (GC-C) receptor. Both Synergy’s lead GC-C agonist,
plecanatide, and next-generation GC-C agonist, SP-333, mimic uroguanylin’s
natural functions by binding to and activating the GC-C receptor in the GI
tract to stimulate fluid and transit required for normal bowel function.
Plecanatide is in phase 3 clinical trials for chronic idiopathic constipation
and a phase 2b study for irritable bowel syndrome with constipation. SP-333 is
in phase 2 development for opioid-induced constipation and is also being
explored for ulcerative colitis. For more information please visit
www.synergypharma.com.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20140313005265/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50824027&lang=en

Contact:

Synergy Pharmaceuticals Inc.
Media
Gem Gokmen, 212-584-7610
Mobile: 646-637-3208
ggokmen@synergypharma.com
or
Investor
Bernard Denoyer, 212-297-0020
Mobile: 203-300-8147
bdenoyer@synergypharma.com
 
Press spacebar to pause and continue. Press esc to stop.